KARNOFSKY and his associates first reported on the clinical use of triethylene melamine in April, 1951. They found that triethylene melamine, though similar to nitrogen mustard (methyl-bis[2-chloroethyl]amine or tris[2-chloroethyl]amine) in its pharmacological effects, did not result in as great an incidence of nausea and vomiting as was associated with the use of nitrogen mustard. They also found that when the parenteral dose of triethylene melamine was doubled and given orally it was equally effective.
We first employed triethylene melamine in the spring of 1950 and since that time have treated 75 patients with this drug, the majority of whom have suffered from leukemia or malignant lymphoma. Various reports have been made on the clinical use of triethylene melamine.1 This is the report of our experience with this drug.
The number of patients treated; their diseases, and the response to therapy are briefly summarized in the accompanying Table. In all instances
BOND WH, ROHN RJ, DYKE RW, FOUTS PJ. CLINICAL USE OF TRIETHYLENE MELAMINE: Report of Seventy-Five Cases. AMA Arch Intern Med. 1953;91(5):602–617. doi:10.1001/archinte.1953.00240170028003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.